Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 8/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CCL2 | P13500 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | EED | O75530 | 1/20 | 0.32 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.32 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.32 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.32 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.32 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29492104 | 0.80 | NLRP3 (0.75) | NLRP3EEDRBBP4SUZ12EZH2 | |
| SCHEMBL24076988 | 0.76 | NLRP3 (0.59) | NLRP3SMN1; SMN2BRD4 | |
| SCHEMBL24077285 | 0.73 | NLRP3 (0.58) | NLRP3KDM4EALDH1A1 | |
| SCHEMBL26909947 | 0.69 | NLRP3 (0.47) | NLRP3 | |
| SCHEMBL25357321 | 0.68 | NLRP3 (0.53) | NLRP3POLB | |
| SCHEMBL29492112 | 0.68 | NLRP3 (0.53) | NLRP3POLB | |
| SCHEMBL25355877 | 0.68 | NLRP3 (0.38) | NLRP3POLBEEDRBBP4SUZ12 | |
| SCHEMBL25428366 | 0.68 | NLRP3 (0.58) | NLRP3KDM4EALDH1A1 | |
| SCHEMBL23950977 | 0.67 | NLRP3 (0.55) | NLRP3 | |
| SCHEMBL29492036 | 0.66 | NLRP3 (1.00) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4217346-B1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-02 | — | — | EP | disclosed |
| US-20230391756-A1 | NEW COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2023-12-07 | — | — | US | disclosed |
| EP-4217346-A1 | NEW COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022063876-A1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391756-A1 | NEW COMPOUND | NLRP3, NLRP1, IL1R1 | NLRP3 1/4885KDM4E 4394/4885ALDH1A1 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.